Prognostic significance of raised serum tumor markers (STM) after 2 cycles of chemotherapy in men with intermediate- and poor-risk non-seminomatous testicular germ cell tumors (NSGCT) treated at a single-centre in India.

Authors

ANKUR NANDAN VARSHNEY

All India Institute of Medical Science (AIIMS), New Delhi, India

ANKUR NANDAN VARSHNEY , Abhishek Raj , Ranjit Kumar Sahoo , Haresh KP , Prabhjot Singh , Shamim Ahmed Shamim , Amlesh Seth , M D INDIA INSTITUTE OF MEDICAL Ray , Seema Kaushal , Chandan Krushna Das , Atul Batra

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

Prognostic factor for overall survival in the "difficult-to-treat" germ cell tumor patients.

First Author: Terukazu Nakamura

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Perioperative morbidity and mortality with bleomycin in primary mediastinal non seminomatous germ cell tumor (PMNSGCT).

First Author: Praveen Ranganath

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).

First Author: Fadi Taza

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).

First Author: Darren R. Feldman